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Abstract
Aims/hypothesis—Young children who develop multiple autoantibodies (mAbs) are at very 
high risk for type 1 diabetes. We assessed whether a population with mAbs detected by screening 
is also at very high risk, and how risk varies according to age, type of autoantibodies and 
metabolic status.
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Methods—Type 1 Diabetes TrialNet Pathway to Prevention participants with mAbs (n = 1815; 
age, 12.35 ± 9.39 years; range, 1– 49 years) were analysed. Type 1 diabetes risk was assessed 
according to age, autoantibody type/number (insulin autoantibodies [IAA], glutamic acid 
decarboxylase autoantibodies [GADA], insulinoma-associated antigen-2 autoantibodies [IA-2A] 
or zinc transporter 8 autoantibodies [ZnT8A]) and Index60 (composite measure of fasting C-
peptide, 60 min glucose and 60 min C-peptide). Cox regression and cumulative incidence curves 
were utilised in this cohort study.
Results—Age was inversely related to type 1 diabetes risk in those with mAbs (HR 0.97 [95% 
CI 0.96, 0.99]). Among participants with 2 autoantibodies, those with GADA had less risk (HR 
0.35 [95% CI 0.22, 0.57]) and those with IA-2A had higher risk (HR 2.82 [95% CI 1.76, 4.51]) of 
type 1 diabetes. Those with IAA and GADA had only a 17% 5 year risk of type 1 diabetes. The 
risk was significantly lower for those with Index60 <1.0 (HR 0.23 [95% CI 0.19, 0.30]) vs those 
with Index60 values ≥1.0. Among the 12% (225/1815) ≥12.0 years of age with GADA positivity, 
IA-2A negativity and Index60 <1.0, the 5 year risk of type 1 diabetes was 8%.
Conclusions/interpretation—Type 1 diabetes risk varies substantially according to age, 
autoantibody type and metabolic status in individuals screened for mAbs. An appreciable 
proportion of older children and adults with mAbs appear to have a low risk of progressing to type 
1 diabetes at 5 years. With this knowledge, clinical trials of type 1 diabetes prevention can better 
target those most likely to progress.
Keywords
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Introduction
Findings from birth cohorts of young children at high familial or genetic risk for type 1 
diabetes have shown that those who develop multiple autoantibodies (mAbs) are at very high 
risk for type 1 diabetes [1–5]. In fact, it has been proposed that the presence of mAbs is 
already indicative of the eventual progression to clinical type 1 diabetes [5, 6]. However, 
cohorts of individuals with mAbs that are identified by screening might not have the same 
risk for several reasons. For example, a vast majority of their positive autoantibodies are 
prevalent rather than incident. Also, the risk of type 1 diabetes is inversely associated with 
age [2, 7] and cohorts screened for autoantibodies are appreciably older than birth cohorts. 
Moreover, screened cohorts might differ in autoantibody types and metabolic status; either 
or both could influence type 1 diabetes risk.
There is a need to determine whether the likelihood of progression to type 1 diabetes is also 
high in screened cohorts with mAbs. High-risk estimates for type 1 diabetes could have a 
considerable emotional impact and influence the willingness of individuals to enter 
prevention trials. Importantly, accurate risk estimation is critical for developing correct entry 
criteria for type 1 diabetes prevention trials.
Several thousands of children and adults who are relatives of individuals with type 1 
diabetes have been identified as having mAbs through screening in the Type 1 Diabetes 
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TrialNet Pathway to Prevention (PTP) study. These individuals are followed for diagnostic 
surveillance of type 1 diabetes with repeat oral glucose tolerance testing (OGTT). This 
information has provided the opportunity to confirm previous findings and assess the extent 
that type 1 diabetes risk varies specifically in children and adults with mAbs.
Methods
Participants
Data from the Type 1 Diabetes TrialNet PTP study were utilised [8]. Participants in the PTP 
study are relatives of individuals with type 1 diabetes. For inclusion in our analysis, 
individuals required the presence of multiple (≥2) autoantibodies on at least one laboratory 
draw, found at a screening visit. Participants either had mAbs at enrolment or became 
positive later, though the vast majority were the former. Islet autoantibody testing (starting in 
2001) was initially assessed by radioimmunoassay for glutamic acid decarboxylase 
autoantibodies (GADA), insulin autoantibodies (IAA) and insulinoma-associated antigen-2 
autoantibodies (IA-2A) [9]. Zinc transporter 8 autoantibodies (ZnT8A) [10] were assessed 
(by radioimmunoassay) if any of the three autoantibodies initially tested were positive at 
screening. ZnT8A testing was initiated in January 2012, with limited testing from 2004–
2008, and participants were included only if they had complete testing for all four 
autoantibodies of interest. Participants were followed in the TrialNet PTP study for the 
development of type 1 diabetes with 2 h OGTTs performed every 6 months. Participants 
with normoglycaemia or dysglycaemia (fasting glucose 5.5–6.9 mmol/l; 30, 60 or 90 min 
glucose ≥11.1 mmol/l; or 2 h glucose 7.8–11.0 mmol/l) were able to enrol. Those with 
OGTTs at baseline indicative of diabetes (fasting glucose ≥7.0 mmol/l or 2 h glucose ≥11.1 
mmol/l) or those missing OGTT time-point data at baseline (at the start of OGTT 
monitoring) were excluded. A minimum of one follow-up monitoring visit was required. 
BMI values obtained within 9 months of the baseline OGTT were used if missing at 
baseline. A diagnosis of type 1 diabetes in the TrialNet PTP study was made if an OGTT 
was in the range for diabetes and this was confirmed on repeat participants continue to be 
followed. Additionally, a clinical diagnosis was made (i.e. symptomatic hyperglycaemia). 
Informed consent and assent, where applicable, was obtained for all study participants and 
all participating clinical sites have been approved by an institutional review board.
Procedures
Participants were evaluated for the following risk predictors of progression to type 1 
diabetes: age, autoantibody type, positivity for 2 vs >2 autoantibodies, normoglycaemia vs 
dysglycaemia, and Index60 <1.0 or ≥1.0 (Index60 = [0.3695 × (log10[fasting C-peptide])] + 
[0.0165 × 60 min glucose] – [0.3644× 60 min C-peptide]). Based on both glucose and C-
peptide measurements, Index60 has been used as a metabolic marker of progression to type 
1 diabetes [11, 12]. An Index60 threshold value of ≥1.0 was employed to indicate metabolic 
impairment [12].
Data analysis
Factors and measures of interest were summarised overall as well as within mAb subgroups 
(e.g. positive for 2 vs 3–4 autoantibodies). Two-sample t tests (or Wilcoxon rank sum tests 
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for comparisons of small subgroups) and χ2 tests were used to compare continuous and 
categorical measures between subgroups. Time of progression to type 1 diabetes and 
cumulative incidence distributions were compared between subgroups using univariate and 
multivariate Cox regression analysis. Adjustments were made for autoantibody number. 
Also, interaction terms were utilised to investigate the influence of age, BMI, sex and 
relationship to proband. Kaplan–Meier and cumulative incidence models were used to 
estimate risk of type 1 diabetes at specific time points of interest. TrialNet PTP participant 
mAb status was determined based on IAA, GADA, IA-2A and ZnT8A. SAS software 
(version 9.4; SAS Institute, Cary, NC, USA) was utilised for computation in the analysis.
Results
The study population of TrialNet PTP participants included 10,020 autoantibody positive 
individuals, with 4145 confirmed single-autoantibody positive and 5875 mAb-positive 
participants (electronic supplementary material [ESM] Fig. 1). Individuals were excluded if 
they did not have complete OGTT data, autoantibody testing data, at least one follow-up 
visit, or age and BMI data. Individuals were also excluded if they had an OGTT in the 
diabetes range at baseline. Brief characteristics of those excluded are presented in ESM 
Table 1. A total of 1815 mAb-positive individuals were included in the analysis, divided into 
those with 2 (n = 804) and 3–4 (i.e. >2; n = 1011) autoantibodies (GADA, IAA, IA-2A, 
ZnT8A). Ninety per cent were first-degree relatives of individuals with type 1 diabetes. 
Baseline characteristics of those included are in Table 1. Individuals included had necessary 
data for analysis (sex was missing in n = 9). The mean (±SD) follow-up time of the cohort 
was 2.40 ± 2.35 years. Across the overall cohort, the age and BMI were 12.35 ± 9.39 years 
and 19.66 ± 5.39 kg/m2, respectively, with 46.3% of participants being female. Those with 
only 2 autoantibodies were, on average, significantly older (p = 0.0310) than those with >2 
autoantibodies, but with similar BMI values (p = 0.4936). There was a similar proportion of 
female participants among those with 2 autoantibodies and >2 autoantibodies (p = 0.2701).
Age
There was an inverse association between type 1 diabetes and age (continuous variable) in 
those with mAbs (HR 0.97 [95% CI 0.96, 0.99]; p = 0.0004). This pattern is evident in Fig. 
1, which shows a significantly lower cumulative incidence among those ≥12.0 years of age 
than those <12.0 years of age, with both 2 and >2 autoantibodies, as has been demonstrated 
in birth cohorts and other screened populations. Specifically, participants who were <12.0 
years of age at mAb determination (n = 1145) had an estimated 5 year type 1 diabetes rate of 
35% (95% CI 31%, 40%) vs those who were ≥12.0 years of age (n = 670), who had an 
estimated 5 year type 1 diabetes rate of 22% (95% CI 17%, 28%) (HR 0.62 [95% CI 0.48, 
0.80]; p = 0.0002). Among those >18 years of age (n =253), the 5 year type 1 diabetes rate 
was low at 15% (95% CI 9%, 24%). These arbitrary categories were used to roughly 
describe pre-/peri-pubertal from post-pubertal age groups.
Number and type of autoantibodies
The cumulative incidence of diabetes at 5 years of follow-up in those with 2 vs >2 
autoantibodies at baseline was 29% and 31%, respectively. We assessed the risk of type 1 
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diabetes according to the types of autoantibodies that were present (ESM Table 2). In Cox 
regression models adjusting for the number of autoantibodies (2, 3 or 4), the presence of 
GADA conferred a lower risk of type 1 diabetes relative to the presence of other 
autoantibodies (HR 0.60 [95% CI 0.43, 0.85]; p = 0.0038). In contrast, IA-2A positivity 
conferred a higher risk relative to the presence of other autoantibodies (HR 1.97 [95% CI 
1.47, 2.64]; p < 0.0001). IAA and ZnT8A were associated with an increased risk of type 1 
diabetes in the univariate setting, but not after adjustment for the number of positive 
autoantibodies.
Figure 2 focuses on GADA and IA-2A, the lowest risk and highest risk autoantibodies, 
respectively. It shows the cumulative incidence curves for type 1 diabetes among those with 
2 autoantibodies who had either GADA or IA-2A as one of two autoantibodies (those 
positive for both GADA and IA-2A were excluded). The risk for type 1 diabetes was 
significantly lower in those positive for GADA as one of the two autoantibodies (in the 
absence of IA-2A) (HR 0.35 [95% CI 0.22, 0.57]; p < 0.0001). Conversely, those positive for 
IA-2A (in the absence of GADA) were at significantly increased risk of type 1 diabetes (HR 
2.82 [1.76, 4.51]; p < 0.0001). The 5 year risk estimates were 21% vs 60% for GADA-
positive (without IA-2A) vs IA-2A-positive (without GADA) participants with 2 
autoantibodies (Fig. 2).
Descriptive age differences in autoantibody pairs among those with 2 autoantibodies 
demonstrate what has previously been shown in birth cohorts: those with IAA (IAA/GADA, 
IAA/ZnT8A and IAA/IA-2A) were younger (ESM Fig. 2a). The combination of IAA/
GADA was most common among those with 2 autoantibodies (41%) and provided the 
lowest risk of progression at 5 years compared with other autoantibody pairs (p = 0.0003, 
logrank test). GADA/ZnT8A-positive individuals were the largest group of those who were 
>12.0 years old (40%) (data not shown).
The three autoantibody pairs with the lowest risk of progression to type 1 diabetes at 5 years 
were IAA/GADA (17% [95% CI 12%, 25%]), GADA/ZnT8A (26% [95% CI 17%, 38%]) 
and IAA/ZnT8A (33% [95% CI 14%, 63%]). Those with the highest risk of progression at 5 
years were GADA/IA-2A (40% [95% CI 29%, 54%]) and ZnT8A/IA-2A (54% [95% CI 
34%, 77%]). The sample size of individuals with IAA/IA-2A positivity was low at 5 years; 
the 3 year cumulative incidence was 30% (ESM Fig. 2). For the lowest risk group (IAA/
GADA; see ESM Fig. 2b) at baseline, a longitudinal analysis demonstrated only 26% 
(84/327) of individuals developed IA-2A or ZnT8A during follow up. The 5 year risk of 
progression for those that remained IAA/ GADA-positive was 15% compared with 20% for 
IAA/ GADA-positive participants that developed IA-2A or ZnT8A positivity later. Those in 
the IAA/GADA group who developed IA-2A or ZnT8A were younger (mean ± SD: 7.6 ± 
5.3 years of age) at the age of mAb determination than those who remained IAA/GADA 
positive only during follow up (12.5 ± 10.1 years of age; p < 0.0001).
Metabolic status
The cumulative incidence for type 1 diabetes was lower in those with Index60 values <1.0 vs 
values ≥1.0 in the overall cohort (HR 0.23 [95% CI 0.19, 0.30]; p < 0.0001). These 
differences in risk based on Index60 were seen both among individuals with 2 
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autoantibodies (HR 0.17 [95% CI 0.12, 0.24]; p < 0.0001), and in those with >2 
autoantibodies (HR 0.29 [95% CI 0.22, 0.40]; p < 0.0001). For Index60 values <1.0 vs ≥1.0, 
the 5 year estimated type 1 diabetes risk in those with 2 autoantibodies was 20% vs 68%, 
respectively, and in those with >2 autoantibodies, it was 22% vs 53%, respectively. Similar 
patterns of influence were also observed between individuals classified as being 
normoglycaemic vs dysglycaemic with 2 autoantibodies (HR 0.21 [95% CI 0.15, 0.31]; p < 
0.0001) and >2 autoantibodies (HR 0.32 [95% CI 0.24, 0.43]; p < 0.0001). For 
normoglycaemia vs dysglycaemia, the 5 year estimated type 1 diabetes risk in those with 2 
autoantibodies was 20% vs 65%, respectively, and in those with >2 autoantibodies, it was 
24% vs 49%, respectively.
The association of type 1 diabetes with age is modified by metabolic status (Fig. 3). Among 
those with Index60 values <1.0, the cumulative incidence was much lower in those ≥12.0 
years of age than those <12.0 years of age (p = 0.0009), whereas, among those with Index60 
values ≥1.0, there was no longer a significant difference between the two age groups (p = 
0.2555). The interaction of the influence of age group by Index60 was also evident using the 
multivariable Cox regression model, where there was a significant interaction between age 
and Index60 (p = 0.0019). Other significant interactions included age and BMI (p = 0.0270), 
age and first-degree relative status (p = 0.0193), age and sex (p = 0.0445), and sex and 
Index60 (p = 0.0026) (data not shown).
To demonstrate the aggregate impact of age, type of autoantibodies and Index60 on type 1 
diabetes risk among those with mAbs, we compared a ‘lowest’ risk group (≥12.0 years with 
GADA present, IA-2A absent and Index60 values <1.0) with a ‘highest’ risk group (<12.0 
years old with GADA present or absent [absent would markedly limit numbers], IA-2A 
present and Index60 values ≥1.0). There was a large difference in the cumulative incidence 
of type 1 diabetes between the groups (Fig. 4). The 5 year risk estimate was 61% (number at 
risk: 239/1815; 13% of the cohort) in the highest risk group, whereas it was only 8% in the 
lowest risk group. That latter group comprised 12% (225/1815) of the study population.
Discussion
Type 1 diabetes is increasingly recognised as being a heterogeneous disorder. This is evident 
with regard to age of onset [13], genetic diversity [14–17], differing autoantibody 
associations [18–20] and metabolic differences [21, 22]. Our findings of marked variation in 
risk among those with mAbs in the TrialNet PTP population is consistent with the 
heterogeneity of type 1 diabetes. For each of the characteristics studied (age, autoantibody 
number, autoantibody type and Index60), there were appreciable proportions of individuals 
who appeared unlikely to progress to type 1 diabetes. Moreover, when these characteristics 
were combined, a sizeable proportion of individuals were at lower risk compared with those 
without this combination of characteristics. Even among those with >2 autoantibodies, the 
ultimate progression to type 1 diabetes was still questionable in a considerable number at 5 
years of follow up.
The findings presented here suggest that the risk associated with mAbs differs between 
cohorts defined by incident autoantibodies (such as birth cohorts) and cohorts defined 
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through screening at-risk relatives of individuals with type 1 diabetes. The latter cohorts are 
predominantly comprised of those with prevalent mAbs, such as the TrialNet PTP. Incident 
autoantibodies could be indicative of more aggressive disease. It is possible that a good 
proportion of prevalent autoantibodies are long-standing and, thus, representative of less 
progressive disease, especially if first identified in later childhood or adulthood. Our study 
confirms several findings from birth cohorts and smaller screened populations and adds to 
the current literature regarding individuals at risk for type 1 diabetes with mAbs, in addition 
to identifying a subgroup of individuals with relatively low risk of progression.
The inverse association of type 1 diabetes with age has been shown in several cohorts [2, 4, 
5, 13, 20]. Data from TrialNet [23] and birth cohorts, such as The Environmental 
Determinants of Diabetes in the Young (TEDDY) [15], suggest that the association of type 1 
diabetes with age is complex and dependent on the timing of the appearance of 
autoantibodies. Lower risk has been associated with GADA and higher risk has been 
associated with IA-2A and ZnT8A in autoantibody positive populations; however, most 
studies have assessed single autoantibodies and mAbs combined [5, 24]. The lower risk 
conferred by the presence of GADA in a mAb group was also seen in TEDDY, where slower 
progression to diabetes was demonstrated in children with stable GADA positivity but 
lacking IA-2A, regardless of age at seroconversion [25]. It should be emphasised that, 
although GADA was shown to represent a group with lower diabetes risk in our study, it was 
in the context of a mAb-positive population. Thus, our findings do not negate the evidence 
that GADA is a risk factor for type 1 diabetes in the general population, and the 5 year risk 
of diabetes remains higher for individuals with GADA plus another autoantibody compared 
with those with single autoantibodies [26]. The degree of risk for type 1 diabetes with IA-2A 
as one of two positive autoantibodies is similar to those with >2 autoantibodies, confirming 
the high-risk nature of IA-2A seen in birth cohorts and European screened cohort studies [5, 
20, 24, 26, 27].
Perhaps the most surprising finding in our study includes the breakdown of risk by 
autoantibody pairs. Among those with 2 autoantibodies, the 5 year type 1 diabetes risk was 
only 17% among those with IAA and GADA. Birth cohort participants typically develop 
IAA or GADA first, based on age, and later, with the development of mAbs, have a high 
lifetime risk of type 1 diabetes [28]. Our study confirms the Belgian Diabetes Registry 
findings of Gorus et al [20] in that participants with IAA/GADA had a lower risk of type 1 
diabetes compared with other autoantibody pairs. In addition, we further assessed type 1 
diabetes risk in all autoantibody pairs. It is evident that the prognostic implications for 
autoantibody combinations can be quite different between incident data from birth cohorts 
and prevalence data from screened cohorts.
The lower risk related to IAA/GADA positivity in screened cohorts compared with birth 
cohorts may not entirely be related to older age, since the median age of individuals with 
combined IAA and GADA in our cohort was less than 10 years. Intermolecular antigen 
spreading, specifically following IAA seroconversion, is thought to occur in early childhood 
[23, 29]. As the majority of individuals with IAA/ GADA at mAb determination did not 
develop IA-2A or ZnT8A over the time of monitoring in our study, they may have already 
passed this antigen spreading time. Based on our results, among those with 2 autoantibodies, 
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autoantibody positive pairs at baseline screening can predict risk of progression, providing a 
more personalised approach to clinical trial recruitment and facilitating recruitment of higher 
risk participants in prevention clinical trials.
Also, the similar risk for type 1 diabetes between those with 2 and those with >2 
autoantibodies was notable. This differs from findings in other studies where individuals 
with increasing numbers of autoantibodies in the Diabetes Prevention Trial–Type 1 and in 
birth cohorts have the highest risk of progression [2, 5, 13]. The basis for this difference is 
not clear. A possible explanation is that once metabolic disturbances are present (e.g. 
elevated Index60 or dysglycaemia), the difference in risk between having 2 and >2 
autoantibodies (from IAA, GADA, IA-2A and ZnT8A) is not significant. However, in the 
Diabetes Prevention Trial–Type 1 study, which showed a higher risk among those with >2 
autoantibodies [19], individuals were screened for islet cell autoantibodies (ICA), which we 
excluded, and the autoantibody to ZnT8 had not been discovered at that time. Moreover, as 
mentioned above, birth cohorts can differ markedly from prevalence cohorts regarding the 
prognostic implications of autoantibodies.
Other characteristics of autoantibodies, besides their type, could influence the risk of type 1 
diabetes. For example, it has become apparent that autoantibody affinity is a critical 
characteristic that should also be taken into account: single GADA and single IAA 
autoantibodies that are positive by electrochemiluminescence are indicative of much higher 
risk of type 1 diabetes than those that are negative [30–32]. Autoantibody titre also appears 
to affect the risk of type 1 diabetes [7, 18, 33, 34] and would be valuable data to add in 
future studies.
Measures of metabolic status, such as insulin, C-peptide, glucose, and combinations of C-
peptide and glucose, have also been shown to be predictive of type 1 diabetes [11, 21, 22, 
35]. For example, ICA-positive relatives of individuals with type 1 diabetes in the large 
European Nicotinamide Diabetes Intervention Trial (ENDIT) demonstrated clear 
augmentation of risk of progression to diabetes over 5 years based on dysglycaemia and the 
first phase insulin response [22]. In our analysis, we focused on Index60, a novel and 
composite marker of C-peptide and glucose, in addition to analysing a well-known 
metabolic marker (impaired blood glucose level). The presence of Index60 ≥1.0 or 
dysglycaemia placed participants at substantial risk for type 1 diabetes. Other risk factors, 
such as age, were less impactful in the presence of metabolic abnormalities.
The variability in risk of type 1 diabetes has been clearly demonstrated in this study in 
individuals with relatives who have type 1 diabetes, as well as in birth cohorts and smaller 
screened populations [5, 7, 14, 18, 20, 25, 27, 33]. In our study, we identified a subset of 
participants with low risk of progression based on age, autoantibody type and metabolic 
status. In comparison, using a combination of birth and screened cohorts across a broad age 
range but a smaller sample size, Long et al [36] did not demonstrate autoantibody 
differences in individuals characterised as slow progressors (diabetes-free 10 years after 
mAb determination). The Diabetes in Autoimmunity Study in the Young (DAISY) birth 
cohort identified mAb-positive slow progressors that were set apart from rapid progressors 
by IAA titre and the rate of progression from single to mAb positivity [7].
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Assessing this risk of progression for potential enrolment in prevention trials is not without 
difficulty. However, the consideration of autoantibody types (beyond the number of 
autoantibodies) could itself provide a more refined and efficient selection of research 
participants, or at least improve the selection of those who should have metabolic testing. 
The change in autoantibodies over time has also been shown to impact risk, such as the loss 
of IAA [20].
Our study has certain limitations. The findings might not be fully representative of other 
cohorts screened for autoantibodies, especially if entry criteria differ from those of the 
TrialNet PTP study. Autoantibody titre and affinity, as well as genotype, were not assessed. 
Additionally, 5 year risk estimates are not necessarily indicative of the likelihood of long-
term progression to type 1 diabetes.
This study also has certain strengths. The TrialNet PTP study has a large, diverse population 
that is sufficient in number for the more subtle subgroup analyses on which much of our 
findings were based. Also, participants in the TrialNet PTP have been well characterised 
with regard to both autoantibody and metabolic status.
It has been proposed that progression to type 1 diabetes should be viewed in terms of three 
stages, with the first being the development of mAbs, followed by dysglycaemia in the 
presence of mAbs and, finally, metabolic decompensation and onset of clinical diabetes [6]. 
Although this staging paradigm could be appropriate for many who have progressed to type 
1 diabetes, our findings, in addition to previous works discussed here, suggest that this does 
not apply to all; i.e. individuals who have mAbs do not necessarily progress to type 1 
diabetes. Importantly, our findings not only show that type 1 diabetes risk varies 
substantially in a population with mAbs, but that appreciable numbers of individuals who 
appear unlikely to progress to type 1 diabetes can be identified. With this knowledge, 
prevention clinical trials can better target those most likely to progress to type 1 diabetes and 
enrolment criteria can be designed with these features in mind.
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Research in context
What is already known about this subject?
• Young children with multiple islet autoantibodies who are followed in birth 
cohorts have a very high risk of progression to type 1 diabetes
• The risk of progression to type 1 diabetes in those with multiple autoantibody 
(mAb) positivity detected by screening has not been fully assessed according 
to population characteristics, and this population remains the largest pool for 
prevention trials
What is the key question?
• What is the risk of progression to type 1 diabetes in a screened population 
with mAbs and what factors affect this risk?
What are the new findings?
• Age, autoantibody type and metabolic status were confirmed to each 
appreciably influence the risk of type 1 diabetes progression in a large 
screened cohort
• Among the 12% (225/1815) ≥12.0 years of age who were positive for 
glutamic acid decarboxylase autoantibodies (GADA), negative for 
insulinoma-associated antigen-2 autoantibodies (IA-2A), and had Index60 
values (a composite glucose and C-peptide measure) <1.0, the 5 year risk of 
type 1 diabetes was 8%
How might this impact on clinical practice in the foreseeable future?
• These findings add to the current literature to improve our understanding of 
the prognosis for clinical disease in individuals with mAbs, and may help to 
suggest a more specific selection of mAb-positive participants for type 1 
diabetes prevention trials
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Fig. 1. 
Cumulative incidence with 95% CI (shaded area) of type 1 diabetes in TrialNet PTP 
participants with (a) 2 autoantibodies (p = 0.0496, logrank test) or (b) >2 autoantibodies (p 
= 0.0008, logrank test). Red, <12 years of age; blue, ≥12 years of age
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Fig. 2. 
Cumulative incidence with 95% CI (shaded area) of type 1 diabetes in participants with 2 
autoantibodies, including either IA-2A without GADA (red) or GADA without IA-2A (blue) 
(p < 0.0001, logrank test)
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Fig. 3. 
(a) Cumulative incidence with 95% CI (shaded area) of type 1 diabetes in participants with 
mAbs with Index60 ≥1.0 (red) or Index60 <1.0 (blue) (p < 0.0001, logrank test). (b, c) 
Cumulative incidence with 95% CI (shaded area) of type 1 diabetes in participants aged <12 
years (red) and ≥12 years (blue) with Index60 values <1.0 (p = 0.0009, logrank test) (b) or 
≥1.0 (p = 0.2555, logrank test) (c)
Jacobsen et al. Page 16
Diabetologia. Author manuscript; available in PMC 2020 May 17.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Fig. 4. 
Cumulative incidence with 95% CI (shaded area) of type 1 diabetes in the ‘highest’ risk 
group (<12 years, IA-2A present, GADA present or absent and Index60 values ≥1.0; red) 
compared with the ‘lowest’ risk group (≥12 years, GADA present without IA-2A, Index60 
values <1.0; blue) (p < 0.0001, logrank test)
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Table 1
Baseline characteristics of mAb-positive participants
Baseline characteristic 2 Ab+ >2 Ab+ p value
n (%) 804 (44.3) 1011 (55.7)
Age, years 13.29 ± 10.44 11.61 ± 8.39 0.0310
BMI, kg/m2 19.86 ± 5.72 19.49 ± 5.12 0.4936
Sex, n (%)a 0.2701
  Female 381 (47.74) 455 (45.14)
  Male 417 (52.26) 553 (54.86)
Follow-up, years 2.49 ± 2.45 2.33 ± 2.27 0.3025
T1D events, n (%) 122 (15.17) 183 (18.10)
Antibodies, n (%)
  GADA <0.0001
    Negative 122 (15.17) 44 (4.35)
    Positive 682 (84.83) 967 (95.65)
  IA-2A <0.0001
    Negative 586 (72.89) 164 (16.22)
    Positive 218 (27.11) 847 (83.78)
  IAA <0.0001
    Negative 414 (51.49) 320 (31.65)
    Positive 390 (48.51) 691 (68.35)
  ZnT8A <0.0001
    Negative 486 (60.45) 107 (10.58)
    Positive 318 (39.55) 904 (89.42)
Data are presented as mean ± SD or n (%)
a
Data missing for n = 9 individuals (n = 6 for 2 autoantibodies; n = 3 for >2 autoantibodies)
Ab, autoantibody; T1D, type 1 diabetes
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